Roche teams up with genome sequencing pioneer to ID new drug targets

|About: Roche Holding Ltd ADR (RHHBY)|By:, SA News Editor

Roche's (OTCQX:RHHBY) Genentech unit signs a multi-year deal with genome pioneer J. Craig Venter's Human Longevity start-up to sequence and analyze tens of thousands of human genomes. The data will be used to identify new drug targets and biomarkers.

Human Longevity's goal is to sequence 1M genomes by 2020. The transaction will enable it to have access to both genomic and clinical information from patients enrolled in clinical trials. The DNA will be stripped of personal identifying details but will be linked to clinical information.

Financial terms are undisclosed.

Subscribe for full text news in your inbox